• Markets
  • icon
  • Companies
ACW · ASX

Actinogen Medical Limited (ASX:ACW)

AU$0.026

 -0.001 (-3.704%)
ASX:Live
22/05/2024 04:10:12 PM
HALO Ords HALO Earnings Momentum GROWTH AUS All-Consensus All-Companies
Consensus Score
/10
Recommend
Target Price
Deviation
Unlock Full Consensus Insights

ACW Overview

ACW Health Scores

Short Term

Mean Revision

Neutral

Trend

Neutral

Event

Neutral

Halo Model

MQV

Very Strong

GARP

Very Strong

MQV Small

Neutral

Valuation

Value

Consensus

Momentum

Price

Strong

Earnings

Very Weak

Growth

Earnings

Neutral

Dividends

Very Strong

Quality

Capital Efficiency

Very Strong

Balance Sheet

Very Strong

About ACW

Telephone

Address

Description

Actinogen Medical Ltd. is a clinical stage Australian biotechnology company, which focuses on the development of novel treatments or cognitive impairment associated with neurological, psychiatric, and metabolic diseases due to raised cortisol. The company was founded by Geoff E. D. Brooke & David Keast on March 23, 1999 and is headquartered in Sydney, Australia.

ACW Price Chart

Key Stats

Market Cap

AU$67.02M

PE

N/A

EV/EBITDA

N/A

Dividends Overview

DIV Yield

N/A

Franking

N/A

Ex Dividend Date (est.)

N/A

Market Data

52 weeks range

Low 0.01 - 0.06

Trade Value (12mth)

AU$15,792.00

1 week

-3.7%

1 month

-12.13%

YTD

25.53%

1 year

-50.1%

All time high

0.8419219851493835

Key Fundamentals

EPS 3 yr Growth

21.300%

EBITDA Margin

N/A

Operating Cashflow

-$9m

Free Cash Flow Return

-49.40%

ROIC

-61.00%

Interest Coverage

-931.80

Quick Ratio

7.00

Other Data

Shares on Issue (Fully Dilluted)

2339m

HALO Sector

Next Company Report Date

28-Aug-24

Ex Dividend Date (est.)

N/A

Next Dividend Pay Date (est.)

N/A

Reporting Currency

AUD

Short Sell (% of issue)

0.00

ACW Announcements

Latest Announcements

Date Announcements

16 May 24

Change in substantial holding

×

Change in substantial holding

15 May 24

ACWs $3.9m entitlement offer opens & letters distribute

×

ACWs $3.9m entitlement offer opens & letters distribute

14 May 24

Application for quotation of securities - ACW

×

Application for quotation of securities - ACW

14 May 24

Cleansing Notice

×

Cleansing Notice

14 May 24

Notification regarding unquoted securities - ACW

×

Notification regarding unquoted securities - ACW

13 May 24

ACW Clinical Trials Science Forum 23 May registration detail

×

ACW Clinical Trials Science Forum 23 May registration detail

08 May 24

Application for quotation of securities - ACW

×

Application for quotation of securities - ACW

07 May 24

Prospectus - Non-renounceable Entitlement Offer

×

Prospectus - Non-renounceable Entitlement Offer

07 May 24

ACW lodges Prospectus for entitlement offer of up to $3.9m

×

ACW lodges Prospectus for entitlement offer of up to $3.9m

03 May 24

Actinogen announces capital raising of up to $8.9 million

×

Actinogen announces capital raising of up to $8.9 million

03 May 24

Proposed issue of securities - ACW

×

Proposed issue of securities - ACW

01 May 24

Trading Halt

×

Trading Halt

30 April 24

ACW March 2024 quarterly activity report & Appendix 4C

×

ACW March 2024 quarterly activity report & Appendix 4C

22 April 24

ACW completes cognition & depression phase 2 trial enrolment

×

ACW completes cognition & depression phase 2 trial enrolment

15 April 24

Notification of cessation of securities - ACW

×

Notification of cessation of securities - ACW

15 April 24

First patient treated in ACW XanaMIA ph 2b Alzheimers trial

×

First patient treated in ACW XanaMIA ph 2b Alzheimers trial

05 April 24

Notification of cessation of securities - ACW

×

Notification of cessation of securities - ACW

05 April 24

Appendix 3Y-Mr Malcolm McComas

×

Appendix 3Y-Mr Malcolm McComas

03 April 24

Application for quotation of securities - ACW

×

Application for quotation of securities - ACW

25 March 24

ACW corporate presentation revised licensing slide

×

ACW corporate presentation revised licensing slide

20 March 24

Actinogen corporate presentation March 2024

×

Actinogen corporate presentation March 2024

20 March 24

Notification of buy-back - ACW

×

Notification of buy-back - ACW

07 March 24

ACW XanaCIDD depression trial enters final enrolment phase

×

ACW XanaCIDD depression trial enters final enrolment phase

07 March 24

Application for quotation of securities - ACW

×

Application for quotation of securities - ACW

06 March 24

Actinogen CMO presents at ADPD 2024 conference

×

Actinogen CMO presents at ADPD 2024 conference

ACW Fundamentals

Per Share Records

Historical data

Forecasted data

AUD 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026
Per Share, Growth & Valuations
EPS (Basic) $ Lock Lock Lock Lock -0.00 -0.01 -0.01 Lock Lock Lock
EPS (Fully Diluted) $ Lock Lock Lock Lock -0.00 -0.01 -0.01 Lock Lock Lock
     Growth % Lock Lock Lock Lock 40.4 -96.4 -3.6 Lock Lock Lock
     PE X Lock Lock Lock Lock N/A N/A N/A Lock Lock Lock
     EV/EBITDA X Lock Lock Lock Lock N/A N/A N/A Lock Lock Lock
CFPS $ Lock Lock Lock Lock -0.00 -0.00 -0.00 Lock Lock Lock
FCFPS $ Lock Lock Lock Lock -0.00 -0.01 -0.00 Lock Lock Lock
     Growth % Lock Lock Lock Lock 53.0 -123.3 -7.2 Lock Lock Lock
     Yield % Lock Lock Lock Lock -0.9 -11.1 -12.1 Lock Lock Lock
DPS $ Lock Lock Lock Lock 0.00 0.00 0.00 Lock Lock Lock
     Growth % Lock Lock Lock Lock N/A N/A N/A Lock Lock Lock
     Yield % Lock Lock Lock Lock N/A N/A N/A Lock Lock Lock
     Payout Ratio % Lock Lock Lock Lock 0 0 0 Lock Lock Lock
BPS $ Lock Lock Lock Lock 0.01 0.01 0.01 Lock Lock Lock
BPS (Tangible) $ Lock Lock Lock Lock 0.01 0.01 0.01 Lock Lock Lock
     Growth % Lock Lock Lock Lock 31.2 21.9 -45.1 Lock Lock Lock
Shares Outstanding
Diluted m Lock Lock Lock Lock 1,405 1,717 1,876 Lock Lock Lock
Basic m Lock Lock Lock Lock 1,405 1,717 1,876 Lock Lock Lock

Financial Records

Historical data

Forecasted data

AUD 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026
Income Statement
Sales $m Lock Lock Lock Lock 0 0 0 Lock Lock Lock
     Growth % Lock Lock Lock Lock N/A N/A N/A Lock Lock Lock
Selling & General Expenses $m Lock Lock Lock Lock 6 13 15 Lock Lock Lock
Gross Income $m Lock Lock Lock Lock 0 0 0 Lock Lock Lock
     Growth % Lock Lock Lock Lock 6.4 -3.6 -1.2 Lock Lock Lock
     Margin % Lock Lock Lock Lock N/A N/A N/A Lock Lock Lock
Cost of Goods Sold to Sales % Lock Lock Lock Lock N/A N/A 0 Lock Lock Lock
EBITDA $m Lock Lock Lock Lock -6 -13 -15 Lock Lock Lock
     Growth % Lock Lock Lock Lock 35.1 -131.5 -21.1 Lock Lock Lock
     Margin % Lock Lock Lock Lock N/A N/A N/A Lock Lock Lock
Depreciation & Amortisation $m Lock Lock Lock Lock 0 0 0 Lock Lock Lock
EBIT $m Lock Lock Lock Lock -6 -13 -16 Lock Lock Lock
     Growth % Lock Lock Lock Lock 33.8 -123.1 -20.5 Lock Lock Lock
     Margin % Lock Lock Lock Lock N/A N/A N/A Lock Lock Lock
Pretax Income $m Lock Lock Lock Lock -6 -13 -16 Lock Lock Lock
Income Taxes $m Lock Lock Lock Lock -2 -4 -5 Lock Lock Lock
Net Income $m Lock Lock Lock Lock -4 -9 -11 Lock Lock Lock
     Growth % Lock Lock Lock Lock 26.6 -142.6 -13.2 Lock Lock Lock
     Margin % Lock Lock Lock Lock N/A N/A N/A Lock Lock Lock
Cash Flow Statement
Net Operating Cash Flow $m Lock Lock Lock Lock -2 -10 -9 Lock Lock Lock
Capital Expenditures $m Lock Lock Lock Lock 0 0 0 Lock Lock Lock
Net Investing Cash Flow $m Lock Lock Lock Lock 0 0 0 Lock Lock Lock
Net Financing Cash Flow $m Lock Lock Lock Lock 10 12 1 Lock Lock Lock
Free Cash Flow $m Lock Lock Lock Lock -2 -10 -9 Lock Lock Lock
     Growth % Lock Lock Lock Lock 39.9 -450.3 8.2 Lock Lock Lock
     Margin % Lock Lock Lock Lock N/A N/A N/A Lock Lock Lock
Franking Balance $m Lock Lock Lock Lock N/A N/A 0 Lock Lock Lock
Balance Sheet
Cash & Short-Term Investments $m Lock Lock Lock Lock 13 16 8 Lock Lock Lock
Total Assets $m Lock Lock Lock Lock 18 23 15 Lock Lock Lock
Long Term Debt $m Lock Lock Lock Lock 0 0 0 Lock Lock Lock
Net Debt $m Lock Lock Lock Lock -13 -16 -8 Lock Lock Lock
Total Liabilities $m Lock Lock Lock Lock 1 2 2 Lock Lock Lock
Equity $m Lock Lock Lock Lock 17 22 13 Lock Lock Lock
Invested Capital Lock Lock Lock Lock 18 22 13 Lock Lock Lock
     Growth % Lock Lock Lock Lock 57.5 23.9 -38.6 Lock Lock Lock
Return Ratios
Return on Assets % Lock Lock Lock Lock -21.3 -40.8 -70.7 Lock Lock Lock
Return on Equity % Lock Lock Lock Lock -22.4 -43.7 -80.2 Lock Lock Lock
Return on Total Capital % Lock Lock Lock Lock -40.8 -66.5 -89.7 Lock Lock Lock
Return on Invested Capital % Lock Lock Lock Lock -27.2 -48.1 -61.0 Lock Lock Lock
Cash Flow Return on Invested Capital % Lock Lock Lock Lock -12.0 -48.2 -49.4 Lock Lock Lock

Ratios Records

Historical data

Forecasted data

AUD 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026
Leverage
Interest Cover X Lock Lock Lock Lock -247.2 -691.2 -931.8 Lock Lock Lock
Debt to EBITDA X Lock Lock Lock Lock 2.4 1.3 0.5 Lock Lock Lock
Net Debt to Equity % Lock Lock Lock Lock -75.5 -74.5 -62.5 Lock Lock Lock
Liquidity
Current Ratio X Lock Lock Lock Lock 19.9 13.8 7.0 Lock Lock Lock
Quick Ratio X Lock Lock Lock Lock 19.9 13.8 7.0 Lock Lock Lock
Cash & ST Inv/Current Assets % Lock Lock Lock Lock 89.1 80.2 66.7 Lock Lock Lock
CFO/Current Liabilities % Lock Lock Lock Lock -228.3 -643.2 -482.8 Lock Lock Lock
Balance Sheet Efficiency
Receivables Turnover X Lock Lock Lock Lock 0.0 0.0 0.0 Lock Lock Lock
Inventory Turnover X Lock Lock Lock Lock N/A N/A 0.0 Lock Lock Lock
Working Capital Turnover X Lock Lock Lock Lock 0.0 0.0 0.0 Lock Lock Lock
Payables Turnover X Lock Lock Lock Lock N/A N/A 0.0 Lock Lock Lock
Asset Turnover X Lock Lock Lock Lock 0.0 0.0 0.0 Lock Lock Lock
Du Pont
Asset Turnover X Lock Lock Lock Lock 0.0 0.0 0.0 Lock Lock Lock
x Pretax Margin % Lock Lock Lock Lock N/A N/A 0.0 Lock Lock Lock
= Pretax Return on Assets % Lock Lock Lock Lock N/A N/A 0.0 Lock Lock Lock
x Tax Rate Complement (1-Tax Rate) % Lock Lock Lock Lock N/A N/A 0.0 Lock Lock Lock
Return on Assets % Lock Lock Lock Lock -21.3 -40.8 -70.7 Lock Lock Lock
x Equity Multiplier (Assets/Equity) % Lock Lock Lock Lock 1.1 1.1 1.1 Lock Lock Lock
Return on Equity % Lock Lock Lock Lock -22.4 -43.7 -80.2 Lock Lock Lock
x Earnings Retention (1-Payout) % Lock Lock Lock Lock 100.0 100.0 100.0 Lock Lock Lock
= Reinvestment Rate (%) % Lock Lock Lock Lock -22.4 -43.7 -80.2 Lock Lock Lock
Operating Cycle
Days of Inventory on Hand Days Lock Lock Lock Lock N/A N/A 0.0 Lock Lock Lock
+ Days of Sales Outstanding Days Lock Lock Lock Lock N/A N/A 0.0 Lock Lock Lock
Operating Cycle Days Lock Lock Lock Lock N/A N/A 0.0 Lock Lock Lock
- Days of Payables Outstanding Days Lock Lock Lock Lock 207.2 588.0 899.9 Lock Lock Lock
Net Operating Cycle Days Lock Lock Lock Lock -207.2 -588.0 -899.9 Lock Lock Lock

Dividends

Key Stats

Ex Dividend Date (est.)

N/A

DIV Yield

N/A

Franking Level

N/A

DPSg

%

Quality Yield

Lock

Falling Divs over next 2

Lock

Values and Recommendations

Key Stats

Consensus Score

Lock

Recommendation

Lock

EPS 1 month Change

Lock

Quality Yield

Lock

Falling Divs over next 2

Lock

Halo Consensus Score

Lock Chart

PEG Ratio

Lock Chart

Consensus EPS Revisions

Lock Chart

Short selling

Key Stats

Percent of Issue

0.00%

Value ($M)

0

Prior Change

N/A

7 Day Change

N/A

1 Month Change

N/A

3 Month Change

N/A

Discover
Short-selling
Opportunities

Access data on short interest, stock performance, and potential short-selling candidates across various markets to make informed decisions and optimize your trading strategies.

ACW Shortsell

Frequently Asked Questions

The current share price of Actinogen Medical Limited (ACW:ASX) is AU$0.026.
The 52-week high share price for Actinogen Medical Limited (ACW:ASX) is AU$0.06.
The 52-week low share price for Actinogen Medical Limited (ACW:ASX)? is AU$0.01.
Actinogen Medical Limited (ACW:ASX) does not pay a dividend.
Actinogen Medical Limited (ACW:ASX) does not pay a dividend.
Actinogen Medical Limited (ACW:ASX) has a franking level of 0.0%.
Actinogen Medical Limited (ACW:ASX) is classified in the Healthcare.
The current P/E ratio for Actinogen Medical Limited (ACW:ASX) is .